CD8A and neoplasm: Vaccine therapy aims to break immune tolerance of tumors by exposing antigen presenting cells (APCs) to immunogenic tumor peptides in the hopes of activating a broad lymphocytic immune response involving both CD4+ and CD8+ T-cells.